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1. Introduction
Although surgical resection is the only way to induce
remission (if not cure) in patients with liver meta-
stases (LM) of digestive neuroendocrine tumours (NETS),
it cannot be performed in the vast majority of the
patients due to the diffusion of hepatic disease. Indeed,
despite evolving techniques that may include two-
step resection procedures and liver transplantation,
the proportion of patients who receive liver resection
barely exceeds 15% in specialised centres. Medical and
interventional radiological anti-tumour treatments are
the mainstay for the management of patients with
malignant NETS.
The treatment approach is determined by: the tumour
biology, location of the primary, natural history and
extent of liver involvement. In patients with non-
progressive disease on 2 consecutive CT scans performed
at 6-month intervals, with limited (<50% of the liver
parenchyma), well-differentiated grade 1 or 2 LM, and
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in the absence of major extra-hepatic lesions (mainly
bone metastases), a “watch and wait strategy” can be
proposed.
If one of these conditions is not fulﬁlled, treatment
with long-acting somatostatin analogues might be
proposed in patients with slowly progressive grade 1
tumours, whatever the primary. However, the only
hitherto published prospective study supporting this
indication is in patients with LM of small bowel tumours
(PROMID study). 1
2. Cytotoxic chemotherapy
Intravenous cytotoxic chemotherapy has been proposed
for many years, but most data indicate that it is not
very effective in patients with small bowel primaries.
Streptozotocin-based combinations (with 5-ﬂuorouracil
[5-FU] or doxorubicin) have some efﬁcacy in patients
with malignant pancreatic NETS. However, the high
objective response rates (ORR) of 69% in the study by
Moertel et al. 2 have not been replicated, and most
recent studies report an ORR around 35%. Very recently,
temozolamide-based combinations with 5-FU or its oral
metabolite capecitabine have gained much attention. 3,4
In a retrospective study in 30 naive patients with
malignant pancreatic NETS, a very promising 70% ORR
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was observed, but this ﬁnding is still to be conﬁrmed in
a prospective evaluation. Other combinations, including
oxaliplatin, 5-FU, gemcitabine or irinotecan, have been
proposed, but poorly studied. In patients with grade 3
tumours (KI67 >20%), chemotherapy using cisplatin and
etoposide should be administered whatever the primary.
Although the ORR is high (65%), the duration of response
is short, rarely exceeding 8 months, thereby accounting
for the poor prognosis in these patients.
3. Targeted therapies
Targeted therapies have very recently been shown to
be effective for the treatment of malignant, progressive
Fig. 1 – Kaplan–Meier analysis of progression-free survival
with sunitinib and placebo in advanced pancreatic neu-
roendocrine tumours. Reproduced with permission from
Raymond E, Dahan L, Raoul JL, et al. 5 Sunitinib malate for
the treatment of pancreatic neuroendocrine tumors. N Engl
J Med 2011;364:501−13.
NETS, mainly of pancreatic origin. Sunitinib, a multi-
tyrosine kinase inhibitor with anti-VEGF properties,
prolongs progression-free survival (PFS) in this group
of patients. According to the study by Raymond et al.
(2011), 5 continuous oral intake of sunitinib 37.5mg/day
resulted in a doubling of PFS from 5.5 months to
11.1 months in the placebo and sunitinib groups,
respectively (Fig. 1). The main side effects associated
with sunitinib were hypertension, neutropenia, hand–
foot syndrome, vomiting and hair colour changes.
Everolimus, an inhibitor of the mTOR pathway, has
a similar efﬁcacy in pancreatic NETs. In one of the
largest studies ever performed (>400 patients), an
increase in PFS from 4.6 months with placebo to
11 months with oral everolimus 10mg per day was
observed (Fig. 2). 6 The main side effects associated
with everolimus were stomatitis, diarrhoea, fatigue and
pneumonitis. Everolimus appears to be less effective in
patients with the carcinoid syndrome,most of whom had
small bowel tumours. However, the increase in PFS was
nearly signiﬁcant (11 and 16 months in the placebo and
everolimus groups, respectively). 7
4. Liver-directed therapies
Local ablative therapies, directed to the liver, have yielded
very encouraging results. Hepatic (chemo)embolisation
has been extensively studied, using gelatin sponge
particles or microspheres with or without intra-
arterial chemotherapy with doxorubicin or streptozo-
tocin emulsiﬁed in Lipiodol. 8,9 The main ORR with
chemoembolisation are summarised in Table 1. A recent
prospective study has suggested that the results of
embolisation alone are similar to those of chemo-
embolisation in patients with LM of midgut origin. Most
national or European guidelines advocate ﬁrst-line use of
(chemo)embolisation in this latter group of patients.
Fig. 2 – Kaplan–Meier analysis of progression-free survival with everolimus and placebo in advanced pancreatic
neuroendocrine tumours. Reproducedwith permission fromYao JC, ShahMH, ItoT, et al. 6 Everolimus for advanced pancreatic
neuroendocrine tumors. N Engl J Med 2011;364:514−23.
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Table 1 – Transarterial chemoembolisation results
on tumour load a
N ORR (%) Duration (months)
Dominguez 10 2000 15 53 11
Guptab 11 2003 81 67 17
Loewe 12 2003 23 73 –
Roche 13 2004 64 74 18
Strosberg 14 2006 23 48 –
Marrache 8 2007 67 37 14
Granbergb 15 2007 15 40 6
Hob 16 2007 46 30 –
Dong 17 2010 123 62 –
Whitney 18 2011 28 100 at 3mo –
a All but 2 studies included small bowel and pancreatic primaries.
b TACE or TAE.
5. Conclusions
In conclusion, many medical and locoregional treat-
ments are now available in patients with malig-
nant NETS. Future studies will aim to deﬁne strategies
and order of use, mainly in patients with pancreatic
NETS. Locoregional treatments of LM (both “old” and
“modern”) should be proposed early in the management
of patients with LM of midgut origin.
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